Last reviewed · How we verify
LiquiTears
LiquiTears is an artificial tear solution that lubricates and protects the ocular surface to relieve dry eye symptoms.
LiquiTears is an artificial tear solution that lubricates and protects the ocular surface to relieve dry eye symptoms. Used for Dry eye syndrome / Keratoconjunctivitis sicca.
At a glance
| Generic name | LiquiTears |
|---|---|
| Sponsor | Chakshu Research, Inc. |
| Drug class | Artificial tear / Lubricating ophthalmic solution |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
LiquiTears works by providing topical lubrication to the cornea and conjunctiva, mimicking natural tear film composition. It helps restore moisture to dry eyes and protects the ocular surface from further irritation and damage. The formulation typically contains demulcents and preservatives designed to provide sustained comfort and symptom relief.
Approved indications
- Dry eye syndrome / Keratoconjunctivitis sicca
Common side effects
- Eye irritation
- Blurred vision (transient)
- Allergic reaction to preservatives
Key clinical trials
- Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease (PHASE1)
- Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LiquiTears CI brief — competitive landscape report
- LiquiTears updates RSS · CI watch RSS
- Chakshu Research, Inc. portfolio CI